^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:OncoGxOne™
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Admera HealthType:
Laboratory Developed Test
OncoGxOne™ is a comprehensive 364 gene Next Generation Sequencing assay for profiling all solid tumor types. Input includes both DNA and RNA for optimal fusion detection. OncoGxOne™ measures three types of biomarkers that can help determine if a tumor is likely to respond to these types of therapies. It includes fragment analysis of five well-validated satellite regions recognized by national guidelines.
Cancer:
Solid Tumor
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), EML4 (EMAP Like 4), HER-2 (Human epidermal growth factor receptor 2), MSI (Microsatellite instability)
See More ...
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), EML4 (EMAP Like 4), HER-2 (Human epidermal growth factor receptor 2), MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
Method:
Next-Generation Sequencing (NGS)
